“…In addition, Cathepsin L appears to foster bone degradation by acting as mediator of inflammatory processes associated with these diseases [39,[64][65][66][67][68][69]78]. Furthermore, clinical studies highlight that the expression levels of this enzyme are deregulated in several diseases associated with an altered bone turnover such as osteoporosis [15,35,51,67,73,78], rheumatoid arthritis [15,73,[75][76][77][78][79], osteoarthritis [12,15,75,77], loosened joint prosthesis [77], periodontitis [15,64,65], primary bone tumors [81], bone metastasis [81,82] and related malignant hypercalcemia [5,78,81] (Table 2).…”